How life sciences companies can get involved in the UK’s largest ever health research programme
Accelerating Detection of Disease (ADD) is the UK’s largest ever health research programme. It offers an unparalleled opportunity to support life sciences R&D in healthcare covering diagnostics and treatments, artificial intelligence and digital health.
In this webinar, designed particularly for life sciences companies, the team responsible for delivering ADD will:
- Give an overview of the programme and an update on latest developments
- Set out the opportunity for life sciences organisations to participate
- Answer questions and provide additional clarification on some of the key issues for industry
ADD is being established to deliver a world-leading cohort of 5 million participants over the age of 30 by 2024. It will support research intended to improve the early detection, risk stratification and early intervention for chronic diseases, before symptoms present.
The unrivalled magnitude and depth of the ADD programme will make it a unique resource. Health researchers from industry and academia will have the chance to use ADD to conduct studies that aim to improve the way we detect, diagnose and treat diseases.
ADD has £79 million ISCF funding through UK Research and Innovation, which is being used to set up and begin to deliver the programme. Matched funding of up to £160 million is being sought from industry and charities.